Plotkin, Lilian I.Bellido, Teresita2019-04-302019-04-302016-10Plotkin, L. I., & Bellido, T. (2016). Osteocytic signalling pathways as therapeutic targets for bone fragility. Nature reviews. Endocrinology, 12(10), 593–605. doi:10.1038/nrendo.2016.71https://hdl.handle.net/1805/19025Osteocytes are differentiated osteoblasts that become surrounded by matrix during the process of bone formation. The acquisition of the osteocyte phenotype is achieved by profound modifications in gene expression that confer adaptation to the changing cellular functions and constitute the molecular signature of osteocytes. The levels of expression of genes characteristic of osteoblasts is altered; and the expression of genes/proteins that impart dendritic cellular morphology, regulate matrix mineralization, and control the function of bone surface cells, is orderly modulated during osteocytogenesis. The discovery of human mutations of osteocytic genes had contributed to a large extent to reveal the role of osteocytes in bone homeostasis. Osteocytes are targets of mechanical force imposed to the skeleton and also play a critical role in integrating mechanosensory pathways with the action of hormones, thereby leading to the orchestrated response of bone to environmental cues. Current, novel therapeutic approaches harness this accumulating knowledge by targeting osteocytic signaling pathways and messengers to improve skeletal health.en-USPublisher PolicyBone remodelingFracture healingOsteocytesOsteogenesisOsteoporosisArticle